XPD common variants and their association with melanoma and breast cancer risk.

abstract：PURPOSE:Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear. METHODS:To address these questions, totall...

journal_title：Breast cancer research and treatment

authors： Ni YB,Tsang JYS,Shao MM,Chan SK,Cheung SY,Tong J,To KF,Tse GM

更新日期：2018-05-01 00:00:00

abstract：:The records of 231 patients with primary breast cancer and 85 patients with metastatic breast cancer were reviewed to determine whether indices of body weight were associated with prognosis. Results support previous reports that indices of body weight are relatively weak, but real, prognostic factors. ...

journal_title：Breast cancer research and treatment

authors： Eberlein T,Simon R,Fisher S,Lippman ME

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Existing high-risk clinic models focus on patients with known risk factors, potentially missing many high-risk patients. Here we describe our experience implementing universal risk assessment in an ambulatory breast center. METHODS:Since May 2017, all breast center patients completed a customized intake survey...

journal_title：Breast cancer research and treatment

authors： Weiss A,Grossmith S,Cutts D,Mikami SA,Suskin JA,Graichen MK,Rojas NA,Pace LE,Joyce E,Rhei E,Scheib R,Bychkovsky B,Garber JE,Morganstern D,King TA

更新日期：2019-05-01 00:00:00

abstract：:It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival. Hsp70 and serpinB3 inhibit a lysosomal cell death pathway induced in anthracycline and taxane treated cells, which may be critical for breast cancer cell survival. Thus we ev...

journal_title：Breast cancer research and treatment

authors： Collie-Duguid ES,Sweeney K,Stewart KN,Miller ID,Smyth E,Heys SD

更新日期：2012-04-01 00:00:00

abstract：:We have compared the effects of the progestin R5020 and the antiprogestin RU486 on the growth of the MCF-7 and T47D breast cancer cell lines. Differences between the two compounds were demonstrated in several parameters. 1. Estradiol was required for the efficient inhibition of cell growth of both lines by R5020 but n...

journal_title：Breast cancer research and treatment

authors： Gill PG,Vignon F,Bardon S,Derocq D,Rochefort H

更新日期：1987-10-01 00:00:00

abstract：:Transforming growth factor-β1 (TGF-β1) is negative regulator of cell proliferation and the cell cycle, and plasma levels of TGF-β1 are twice as high in TGF-β1 -509 T homozygotes as in -509 C homozygotes. Published studies on the association between the TGF-β1 gene -509 C/T polymorphism and breast cancer risk are incon...

journal_title：Breast cancer research and treatment

authors： Woo SU,Park KH,Woo OH,Yang DS,Kim AR,Lee ES,Lee JB,Kim YH,Kim JS,Seo JH

更新日期：2010-11-01 00:00:00

abstract：:We showed previously that zerumbone (ZER), a sesquiterpene isolated from subtropical ginger, inhibited in vitro (MCF-7 and MDA-MB-231cells) and in vivo (MDA-MB-231 cells) growth of human breast cancer cells in association with apoptosis induction. Here, we investigated the role of Notch receptors in anticancer effects...

journal_title：Breast cancer research and treatment

authors： Sehrawat A,Sakao K,Singh SV

更新日期：2014-08-01 00:00:00

abstract：BACKGROUND:In several neoplastic diseases, immunosuppression has been shown to correlate with disease stage, progression, and outcome. As the prognosis for metastatic breast cancer is still pessimistic, additional strategies are being sought to improve survival. Local immunosuppression in sentinel node biopsies from 24...

journal_title：Breast cancer research and treatment

authors： Schüle J,Bergkvist L,Håkansson L,Gustafsson B,Håkansson A

更新日期：2002-07-01 00:00:00

abstract：BACKGROUND:Women affected with breast cancer who carry a BRCA1 or BRCA2 (BRCA1/2) mutation are at risk of developing contralateral breast cancer. To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in additio...

journal_title：Breast cancer research and treatment

authors： Graves KD,Peshkin BN,Halbert CH,DeMarco TA,Isaacs C,Schwartz MD

更新日期：2007-09-01 00:00:00

abstract：:Our aim was to analyze the incidence of mutations in BRCA1 and BRCA2 genes in 54 families with breast/ovarian cancer. Families were selected from three Institutions following the standard criteria for hereditary breast/ovarian cancer. PCR amplification of all exons was performed, followed by SSCP, heteroduplex, PTT an...

journal_title：Breast cancer research and treatment

authors： Gallardo M,Silva A,Rubio L,Alvarez C,Torrealba C,Salinas M,Tapia T,Faundez P,Palma L,Riccio ME,Paredes H,Rodriguez M,Cruz A,Rousseau C,King MC,Camus M,Alvarez M,Carvallo P

更新日期：2006-01-01 00:00:00

abstract：:The insulin-like growth factor (IGF)-system plays a role in breast cancer susceptibility as well as in growth and progression of breast carcinomas. So far, findings have been based on serum IGF-I levels and semi-quantitative assessment of IGF-system expression levels in model systems and human tissue. Quantitative dat...

journal_title：Breast cancer research and treatment

authors： Voskuil DW,Bosma A,Vrieling A,Rookus MA,van 't Veer LJ

更新日期：2004-04-01 00:00:00

abstract：PURPOSE:In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1-T2 cN0 early breast cancer and 1-2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3-...

journal_title：Breast cancer research and treatment

authors： Riedel F,Heil J,Feisst M,Moderow M,von Au A,Domschke C,Michel L,Schaefgen B,Golatta M,Hennigs A

更新日期：2020-11-01 00:00:00

abstract：:Mammographic density is a strong and independent risk factor for breast cancer and is considered an intermediate marker of risk. The major predictors of premenopausal mammographic density, however, have yet to be fully elucidated. To test the hypothesis that urinary estrogen metabolism profiles are associated with mam...

journal_title：Breast cancer research and treatment

authors： Bertrand KA,Eliassen AH,Hankinson SE,Gierach GL,Xu X,Rosner B,Ziegler RG,Tamimi RM

更新日期：2012-11-01 00:00:00

abstract：:Mitogenic and growth inhibitory signals influence the activity of a family of cyclin dependent kinases (cdks). p27 is an important cdk inhibitor, acting in G1 to inhibit cyclin-cdks. As negative growth regulators, the cdk inhibitors may function as tumor suppressors. While the p16 gene plays a tumor suppressor role in...

journal_title：Breast cancer research and treatment

authors： Cariou S,Catzavelos C,Slingerland JM

更新日期：1998-01-01 00:00:00

abstract：BACKGROUND:There are concerns regarding local toxicity when IORT is applied in Asian women with a smaller breast volume than that of Western women. Trials are required to develop safety profiles for this technique. The aim of this trial was to evaluate acute toxicity after intra-operative radiotherapy (IORT) with low-e...

journal_title：Breast cancer research and treatment

authors： Ahn SG,Bae SJ,Lee HW,Yoon CI,Kim JW,Lee IJ,Jeong J

更新日期：2019-02-01 00:00:00

abstract：:Weight gain is a common problem amongst women receiving adjuvant chemotherapy for early breast cancer. We undertook a study to determine the causes of this weight gain. Prospective measurements of body mass and composition (skinfolds, bioelectrical impedance, total body potassium), energy balance (resting energy expen...

journal_title：Breast cancer research and treatment

authors： Harvie MN,Campbell IT,Baildam A,Howell A

更新日期：2004-02-01 00:00:00

abstract：:Mutations in breast cancer susceptibility genes, BRCA1 and BRCA2 account for more than 80% of hereditary breast and ovarian cancers. p53 tumor suppressor gene that controls cellular growth and differentiation is also known to be mutated in more than 50% of human cancers including breast cancer. We have carried out a s...

journal_title：Breast cancer research and treatment

authors： Hedau S,Jain N,Husain SA,Mandal AK,Ray G,Shahid M,Kant R,Gupta V,Shukla NK,Deo SS,Das BC

更新日期：2004-11-01 00:00:00

abstract：:Wide fluctuations in results obtained by different laboratories for the content of estrogen receptors from a single source of tissue powder were reported by several investigators at the 1979 NCI Consensus Committee Meeting for Steroid Receptors in Breast Cancer and were further supported by data collected by our labor...

journal_title：Breast cancer research and treatment

authors： Raam S,Gelman R,Faulkner J,White GM,Cohen JL

更新日期：1982-01-01 00:00:00

abstract：:Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive invasive ductal carcinoma accounts for ~45 % of invasive breast cancer (BC) diagnoses in the U.S. Despite reductions in BC mortality attributable to mammography screening and adjuvant hormonal therapy, an important challenge remains the development of...

journal_title：Breast cancer research and treatment

authors： Buas MF,Rho JH,Chai X,Zhang Y,Lampe PD,Li CI

更新日期：2015-09-01 00:00:00

abstract：:We have previously shown that the anti-proliferative effect of retinoic acid in human breast cancer cell line MCF-7 is dependent on HES-1 expression. Here we show that retinoic acid induces HES-1 expression via upregulation of transcription factor SOX9. By expressing a dominant negative form of SOX9, disrupting endoge...

journal_title：Breast cancer research and treatment

authors： Müller P,Crofts JD,Newman BS,Bridgewater LC,Lin CY,Gustafsson JA,Ström A

更新日期：2010-04-01 00:00:00

abstract：:This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

journal_title：Breast cancer research and treatment

authors： Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

更新日期：2004-11-01 00:00:00

abstract：:Previous investigations into the relationship of CAG-repeat lengths in the androgen receptor (AR) gene to female breast cancer (BC) have yielded somewhat confusing results. Decreased AR transactivational activity lowers androgen:estrogen balance, and may thereby effect functional hyperestrogenicity. This may promote t...

journal_title：Breast cancer research and treatment

authors： Elhaji YA,Gottlieb B,Lumbroso R,Beitel LK,Foulkes WD,Pinsky L,Trifiro MA

更新日期：2001-11-01 00:00:00

abstract：:To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new biomarker candidates predicting response to tamoxifen treatment in breast cancer by evaluating these in a meta-analysis of available transc...

journal_title：Breast cancer research and treatment

authors： Mihály Z,Kormos M,Lánczky A,Dank M,Budczies J,Szász MA,Győrffy B

更新日期：2013-07-01 00:00:00

abstract：:The clinical and pathological heterogeneity of breast cancer has instigated efforts to stratify breast cancer sub-types according to molecular profiles. These profiling efforts are now being augmented by large-scale functional screening of breast tumour cell lines, using approaches such as RNA interference. We have de...

journal_title：Breast cancer research and treatment

authors： Sims D,Bursteinas B,Gao Q,Jain E,MacKay A,Mitsopoulos C,Zvelebil M

更新日期：2010-11-01 00:00:00

abstract：:Lysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. We analyzed the prognostic impact of LOXL2 for breast cancer patients and investigated the role of LOXL2 in breast cancer cell lines. Immunohistochemical study of LOXL2 expression was done in samples from 309 patients. Surviv...

journal_title：Breast cancer research and treatment

authors： Ahn SG,Dong SM,Oshima A,Kim WH,Lee HM,Lee SA,Kwon SH,Lee JH,Lee JM,Jeong J,Lee HD,Green JE

更新日期：2013-08-01 00:00:00

abstract：:Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in h...

journal_title：Breast cancer research and treatment

authors： Johnson J,Healey S,Khanna KK,kConFab.,Chenevix-Trench G

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Breakthrough progress has been made in Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Though significant improvements of progression-free survival (PFS) for CDK4/6 inhibitor...

journal_title：Breast cancer research and treatment

authors： Li J,Fu F,Yu L,Huang M,Lin Y,Mei Q,Lv J,Wang C

更新日期：2020-02-01 00:00:00

abstract：:Many epidemiologic features of breast cancer suggest that endogenous hormones are of importance in the genesis of this disease. Endocrinologic studies based on total levels of various hormones in serum and urine have provided etiologic clues, but have failed to yield a clear understanding of the hormonal aberrations t...

journal_title：Breast cancer research and treatment

authors： Thomas DB

更新日期：1986-01-01 00:00:00

abstract：:The polypeptide hormone prolactin (Prl), acting through its cell surface receptors, promotes growth and differentiation in normal and malignant breast cells. We demonstrate herein that two Prl-responsive cell lines, NOG-8 normal mouse mammary epithelial and T47D human breast cancer cells, respond to Prl by rapid and t...

journal_title：Breast cancer research and treatment

authors： Das R,Vonderhaar BK

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

journal_title：Breast cancer research and treatment

authors： O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

更新日期：2018-08-01 00:00:00